EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer

NACompletedINTERVENTIONAL

Timeline

Start Date

June 30, 2003

Study Completion Date

August 31, 2005

Conditions

Cervical Cancer

Interventions

DRUG

EF5

OTHER

immunohistochemistry staining method

PROCEDURE

biopsy

Trial Locations (5)

Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock

Oklahoma University Medical Center, Oklahoma City

Cancer Care Associates - Midtown Tulsa, Tulsa

Colorado Gynecologic Oncology Group P.C., Denver

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT00049231 - EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer | Biotech Hunter | Biotech Hunter